Generic Name: Emflaza

What is Emflaza?

The decision to prescribe selegiline should take into consideration that the MAO system of enzymes is complex and incompletely understood and there is only a limited amount of carefully documented clinical experience with selegiline.

Consequently, the full spectrum of possible responses to selegiline may not have been observed in pre-marketing evaluation of the drug. It is advisable, therefore, to observe patients closely for atypical responses.

Epidemiological studies have shown that patients with Parkinson's disease have a higher risk 2- to approximately 6-fold higher of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, is unclear.

For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using ELDEPRYL for any indication.

Ideally, periodic skin examinations should be performed by appropriately qualified individuals e. Patients should be advised of the possible need to reduce levodopa dosage after the initiation of ELDEPRYL therapy. Patients or their families if the patient is incompetent should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of selegiline should be explained, and a brief description of the 'cheese reaction' provided.

Rare hypertensive reactions with selegiline at recommended doses associated with dietary influences have been reported. Consequently, it may be useful to inform patients or their families about the signs and symptoms associated with MAOI induced hypertensive reactions.

Eldepryl generic generic - what is it. ELDEPRYL Generic name: Selegiline HCl is an anti-Parkinsonism drug approved by the FDA as a supportive therapy to Levodopa and other anti-Parkinsonism drugs. It is an irreversible, first-generation monoamine oxidase MAO inhibitor only acting on a certain form MAO-B at approved dosage levels. With Eldepryl Selegiline HCla MAO-B inhibitor like Rasagiline, and other anti-Parkinsonism drugs, these symptoms of PD are reduced and.

Furthermore, movement and cognitive function are improved. Katzung, 2009 How many people have Parkinsonism. When decreased in levels in Parkinsonism, the effects of excitatory neurotransmitters will continue and will lead to the distinct features in motor and neuropsychiatric symptoms.

To relieve from these symptoms, an enzyme called monoamine oxidase MAO can be irreversibly inhibited. Monoamine oxidase is medically proven to be responsible for the destruction of most of the dopamine after it has been secreted from the neurons in the basal ganglia. These two forms, MAO-A and MAO-B, had been differentiated by their sensitivity to a certain MAO inhibitor clorgyline.

How should I take Emflaza?

Like all medicines, ELDEPRYL tablets can cause side effects. If they occur, most are likely to be minor and temporary. A flexible-dose controlled trial of transdermal selegiline failed to demonstrate efficacy, although the overall safety profile was similar to adults.

In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants SSRIs and others.

What should I avoid while taking Emflaza?

Caution is warranted when darunavir is administered with selegiline as there is a potential for elevated selegiline concentrations. Caution and close monitoring are advised if these drugs are administered together.

Desflurane: Use of monoamine oxidase inhibitors MAOIs with inhaled anesthetics, such as desflurane, may increase the risk of hemodynamic instability during surgery. Caution is advised if these drugs are administered together. Desipramine: Due to the risk of serotonin syndrome, monoamine oxidase inhibitors MAOIs intended to treat psychiatric disorders are contraindicated for use with tricyclic antidepressants TCAs or within 14 days of discontinuing treatment with a TCA.

Emflaza side effects

Advise patients against driving or performing other activities requiring mental alertness until they know how the combination affects them. Palonosetron: Because of the potential risk and severity of serotonin syndrome, use caution when administering palonosetron with other drugs that have serotonergic properties such as Monoamine oxidase inhibitors. Pazopanib: Pazopanib is a weak inhibitor of CYP3A4. Coadministration of pazopanib and selegiline, a CYP3A4 substrate, may cause an increase in systemic concentrations of selegiline.

Use caution when administering these drugs concomitantly.

Common Emflaza ide effects may include:

  • The risk of extrapyramidal effects may be increased during concurrent use of metoclopramide and selegiline, and the therapeutic benefits of selegiline in treating Parkinson's disease may be diminished during use of a central dopamine antagonist such as metoclopramide.

  • Avoid foods and beverages that are high in tyramine, including: aged cheeses e.

  • The strong inhibitory effect of platelet enzyme MAO-B activity after single 10 mg dose lasts over 24 h, and the platelet enzyme MAO-B activity returns to normal level approximately after 2 weeks.

  • Decreases in fetal weight, delayed ossification, and embryo-fetal post-implantation lethality have been noted during the period of organogenesis in animal studies at doses up to 60 times the maximum recommended human dose MRHD.

In vitro studies have shown that transdermal selegiline exhibits antidepressant properties only at doses that inhibit both MAO-A and MAO-B activity in brain. Higher therapeutic doses i. Effects resulting from transdermal selegiline administration may also occur through its metabolites.

However, transdermal dosing results in significantly higher exposure to selegiline with significantly lower exposure for all metabolites relative to oral administration.

Oral selegiline: At doses used in Parkinson's disease, selegiline typically exhibits a greater affinity for MAO-B.

Where can I get more information?

  • Selective serotonin reuptake inhibitors SSRIs - Serious, sometimes fatal, reactions with concomitant use and in patients who have recently discontinued SSRIs particularly fluoxetine and then started on a MAOl.

  • This is a disease of the brain that affects movement.